Related Experiment Video

Updated: Jun 13, 2026

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death
09:18

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death

Published on: December 27, 2016

STAT3 tyrosine phosphorylation influences survival in glioblastoma

Peter Birner1, Kalina Toumangelova-Uzeir, Sevdalin Natchev

  • 1Institute of Neurology, Medical University of Vienna, Vienna, Austria.

Journal of Neuro-Oncology
|May 11, 2010
PubMed

Insights

Activated Signal transducer and activator of transcription protein 3 (STAT3) correlates with shorter survival in glioblastoma patients. STAT3 inhibition may be a viable therapeutic strategy for malignant gliomas.

Area of Science:

  • Neuro-oncology
  • Molecular biology
  • Cancer research

Background:

  • Signal transducer and activator of transcription protein 3 (STAT3) plays a role in CNS development and cancer.
  • STAT3's function in glioblastoma is complex, acting as either an oncogene or tumor suppressor.
  • Understanding STAT3's role is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the prognostic significance of Y705-phosphorylated STAT3 (pY705-STAT3) in glioblastomas and grade III gliomas.
  • To determine the association between pY705-STAT3 levels and patient survival.
  • To evaluate STAT3 activation as a potential therapeutic target in malignant gliomas.

Main Methods:

  • Immunohistochemical assessment of pY705-STAT3 in 111 glioblastoma and 25 grade III glioma specimens.
  • Correlation analysis between pY705-STAT3 expression levels and overall survival.
  • Statistical analysis using Cox regression.

Main Results:

  • High pY705-STAT3 expression in glioblastoma was significantly associated with shorter overall survival (P = 0.001).
  • Similar proportions of high pY705-STAT3 expression were observed in grade III gliomas and glioblastomas.
  • pY705-STAT3 activation indicates more aggressive glioblastoma behavior but not necessarily grade III glioma progression.

Conclusions:

  • STAT3 activation via Y705 phosphorylation is linked to aggressive glioblastoma.
  • STAT3 inhibition is a potential therapeutic strategy for malignant gliomas.
  • STAT3's role in grade III gliomas appears distinct from its role in glioblastoma.

More Related Videos

Three-Dimensional (3D) Tumor Spheroid Invasion Assay12:19

Three-Dimensional (3D) Tumor Spheroid Invasion Assay

Published on: May 1, 2015

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...